NASDAQ:ENSC Ensysce Biosciences Q2 2026 Earnings Report $0.40 0.00 (-1.20%) Closing price 04:00 PM EasternExtended Trading$0.40 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ensysce Biosciences EPS ResultsActual EPS-$0.20Consensus EPS -$0.20Beat/MissMet ExpectationsOne Year Ago EPSN/AEnsysce Biosciences Revenue ResultsActual Revenue$1.16 millionExpected Revenue$1.20 millionBeat/MissMissed by -$35.69 thousandYoY Revenue GrowthN/AEnsysce Biosciences Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time4:00PM ETUpcoming EarningsEnsysce Biosciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Ensysce Biosciences Earnings HeadlinesReviewing Ensysce Biosciences (NASDAQ:ENSC) and Hypermarcas (OTCMKTS:HYPMY)September 29 at 6:14 AM | americanbankingnews.comEnsysce Biosciences Corporate Event Calendar | NASDAQ:ENSCSeptember 9, 2026 | benzinga.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 2 at 1:00 AM | InvestorPlace (Ad)Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks TranscriptAugust 18, 2026 | seekingalpha.comENSC sets itself up nicely for critical stageAugust 14, 2026 | msn.comEnsysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing - The Globe and MailAugust 7, 2026 | theglobeandmail.comSee More Ensysce Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ensysce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ensysce Biosciences and other key companies, straight to your email. Email Address About Ensysce BiosciencesEnsysce Biosciences (NASDAQ:ENSC) is a clinical-stage biotechnology company developing prescription medicines designed to improve the safety of opioid pain treatment. The company focuses on technologies intended to reduce the potential for opioid abuse, misuse, and overdose while preserving analgesic activity. Ensysce’s lead program is PF614, an investigational extended-release oxycodone prodrug being developed with its Trypsin-Activated Abuse Protection (TAAP) technology. The platform is designed to limit the release of active oxycodone when the product is manipulated for non-oral use. Ensysce has also been developing PF614-MPAR, a combination product intended to pair PF614 with an overdose-protection component. The company’s pipeline is aimed primarily at the prescription pain-management market and reflects its broader focus on creating abuse-deterrent and overdose-resistant opioid formulations. Ensysce Biosciences is headquartered in San Diego, California, and its programs remain subject to clinical development and regulatory review.View Ensysce Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
